Eli Lilly draws the line on DTC

Share this article:
Eli Lilly is drawing the line on DTC—at the spots plugging the services of ambulance-chasing trial lawyers. The company surveyed 402 shrinks and found that ads by would-be litigators warning of side effects in anti-psychotics are scaring patients off the drugs.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.